Sergio Traversa is Chief Executive Officer of Relmada Therapeutics, Inc. (RLMD). The company reported total compensation of $8,892,633 for fiscal year 2025.
| Salary | $787,787 |
|---|---|
| Bonus | $2,103,545 |
| Stock awards | — |
| Option awards | $4,951,301 |
| Non-equity incentive plan | — |
| Pension and non-qualified deferred compensation | — |
| All other compensation | $1,050,000 |
| Total | $8,892,633 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Relmada Therapeutics, Inc. filed April 17, 2026, accession 0001213900-26-045192.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sergio Traversa this page | Chief Executive Officer | $8,892,633 |
| Maged Shenouda | Chief Financial Officer | $6,091,453 |
| Charles Ence | Chief Accounting and Compliance Officer | $5,497,026 |
| Paul Kelly | Chief Operating Officer | $5,289,099 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Relmada Therapeutics, Inc. compensation brief.
Sergio Traversa's compensation sits inside Relmada Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.